Guidelines
Guidelines for the safe practice of total intravenous anaesthesia (TIVA) This is a consensus document produced by expert members of a Working Party established by the Association of Anaesthetists and the Society for Intravenous Anaesthesia. It has been seen and approved by the Board of Directors of the Association of Anaesthetists and the Society for Intravenous Anaesthesia. It has been endorsed by the Royal College of Anaesthetists,the College of Anaesthesiologists of Ireland, the Intensive Care Society, the Faculty of Intensive Care Medicine, and the Association of Paediatric Anaesthetists of Great Britain and Ireland.
What other guidelines are available on this topic?
At the time of writing, there were no nationally or internationally agreed guidelines on the use of total intravenous anaesthesia (TIVA).
Why were these guidelines developed?
Surveys of anaesthetists working in the UK and Ireland have concluded that training in TIVA is currently inconsistent and often inadequate and that many anaesthetists do not feel confident when using the technique. The 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia found that self-reported cases of awareness were more common when TIVA was used, but that most of the cases were preventable and that the commonest contributory factor was inadequate education and training [1] . The report anaesthetists have a responsibility to ensure that they have the knowledge and skills required to deliver TIVA competently and safely.
2 When general anaesthesia is to be maintained by propofol infusion, use of a target-controlled infusion (TCI) is recommended. 6 Infusion pumps should be programmed only after the syringe containing the drug to be infused has been placed in the pump. 9 Use of a processed EEG (pEEG) monitor is recommended when a neuromuscular blocking drug is used with TIVA.
10 When TIVA is administered outside the operating room, the same standards of practice and monitoring should apply as for anaesthesia in the operating room.
Introduction
When maintenance of general anaesthesia is by intravenous (i.v.) infusion, this is referred to as TIVA.
Although TIVA has advantages for some patients, and is the preferred technique of some anaesthetists, the commonest technique used for maintenance of anaesthesia in the UK and Ireland remains the administration of an inhaled volatile anaesthetic. 
Achieving a desired drug concentration in the patient
All anaesthetists need to know the pharmacokinetic principles underpinning TIVA to be able to achieve and maintain an appropriate concentration of an i.v. anaesthetic or analgesic drug in the patient's plasma and brain.
Achieving a stable plasma concentration of a drug requires varying drug infusion rates. For example, during induction and maintenance of anaesthesia, a bolus or rapid infusion should be followed by a decreasing infusion rate [2, 3] . The drug concentration achieved in the plasma and brain can be predicted from pharmacokinetic models (Appendix 1).
Anaesthesia may be induced and maintained either using manual dosing, where the anaesthetist determines the bolus dose(s) and infusion rate(s) used, or using a TCI pump where the anaesthetist enters the desired 'target' concentration to be achieved in the patient's plasma or brain.
Target-controlled infusions
A TCI pump contains a microprocessor programmed with pharmacokinetic models for relevant drugs. The user selects the drug and pharmacokinetic model to be used by that TCI pump and inputs the patient characteristics (covariates) such as body weight and age, and the target plasma or 'brain' (effect-site) concentration, with the pump determining the initial bolus and subsequent infusion rates.
The two most commonly used adult propofol models are
Marsh [4] and Schnider [5, 6] . Choosing an appropriate target drug concentration for a patient 
Inter-individual variation
There is considerable variation between patients in the brain propofol concentration required for anaesthesia, as is also the case for volatile anaesthetics [12] . The brain concentration required cannot be predicted in advance, but observation of the patient's response during induction of anaesthesia can give an indication of the approximate propofol concentration that is likely to be required for maintenance. In general, older patients require a lower brain anaesthetic drug concentration than younger patients [6] , but there is considerable variation between individuals of the same age and overlap between patients of different ages. Patients who are ASA physical status 3-5 require particularly careful management. They may require a lower concentration to produce anaesthesia and may become hypotensive during and after the induction period.
Other drugs administered
The administration of opioids, benzodiazepines, ketamine, a 2 -adrenoceptor agonists, magnesium and nitrous oxide result in a marked reduction in the required brain propofol concentration [13, 14] . Synergy of effect occurs between propofol and opioids. Opioids reduce the propofol dose required to produce loss of consciousness and, in particular, to obtund movement and haemodynamic responses to noxious stimuli [15] . A remifentanil infusion is often used in conjunction with propofol infusion. The rapid offset of effect after stopping remifentanil enables doses to be given that reduce propofol requirements by approximately 50% (Table 1 ) without causing prolonged respiratory depression after surgery. However, intra-operative remifentanil does not provide postoperative analgesia. Higher dose remifentanil infusions (target concentration above 5 ng.ml À1 or infusions above 0.2 lg.kg À1 .min À1 ) may cause acute opioid tolerance or opioid-induced hyperalgesia but the clinical significance of this is uncertain [16] .
Degree of surgical stimulus
The brain propofol concentration required for adequate anaesthesia during surgery is influenced by the magnitude of the surgical stimulus. An effective regional anaesthetic block will reduce the propofol concentration required. 
Typical target concentrations in routine practice

Mixing of drugs for infusion
Mixing of propofol and remifentanil in a single syringe is not When TCI anaesthesia is used, additional 'manual'
boluses are usually not required and the target concentration should be increased to deepen anaesthesia.
If a manual bolus is administered, the displayed drug concentrations will be inaccurate for several minutes.
The infusion pump should be visible throughout anaesthesia. The anaesthetist should observe the infusion rate (e.g. ml.h À1 or mg.kg À1 .h À1 ) every few minutes. If, during maintenance of anaesthesia, a TCI pump shuts down due to a depleted battery or has to be restarted due to a malfunction, it is not appropriate to restart TCI anaesthesia using the previous target concentration. If this was done, the pump's calculations would not take into account the drug previously administered and it would give another induction dose by rapid infusion, resulting in an excessively high drug concentration. If a pump does shut down accidently, then it is appropriate to restart it in the manual mode and programme an infusion rate similar to that being delivered at the time of failure.
All vascular access devices used for TIVA should be flushed with at least twice the dead space volume of the device at the end of the procedure. If this is not done, potent anaesthetic drugs (e.g. remifentanil or neuromuscular blocking drugs) may remain in the dead space of a vascular access device and may be accidently administered to the patient postoperatively [24] [25] [26] .
Consent for anaesthesia
As with all medical interventions, the use of TIVA requires an analysis of the risks and benefits for the patient to whom it will be administered. Some observational studies have found an association between TIVA and an increased incidence of accidental awareness during general anaesthesia [1] , whereas others have not [27] . An observational study found an association between TIVA and improved outcome after cancer surgery [28] , but the results of randomised trials are awaited. The anaesthetist should consider what information the patient would wish to know about the technique chosen. However, unbundling all aspects of anaesthetic technique in the consent process may be undesirable and impractical [29] . Balancing uncertain differences in the incidence of complications (e.g. awareness) or benefits (e.g. cancer outcome) against a proven frequent impact (e.g. reduced sickness) is complex.
The Working Party does not consider that use of TIVA per se is an aspect of anaesthetic technique that routinely requires specific formal consent, provided best practice is observed.
Whether consent is required should be assessed on a case by case basis [30] .
Monitoring the patient during TIVA
Monitoring of the patient during TIVA should be in accordance with the Association of Anaesthetists recommendations for standards of monitoring during anaesthesia and recovery [21] . Use of a pEEG monitor is recommended when a neuromuscular blocking drug is used with TIVA. The large majority of cases of self-reported awareness that were identified in NAP5 occurred in patients who had received a neuromuscular blocking drug [1] .
Efforts to prevent awareness should, therefore, focus on During the maintenance phase of anaesthesia with an inhaled agent, it is possible to use the end-tidal anaesthetic gas concentration as an indication that the anaesthetic drug is being delivered as intended; this is not possible during TIVA. Monitoring of the effect of the anaesthetic drug on the cerebral cortex with a pEEG monitor can reduce the likelihood of awareness [31] . The isolated forearm technique can also be used to assess conscious state in paralysed patients [32] [33] [34] ; however, its use to date has largely been confined to research studies.
Almost 20% of the NAP5 reports of awareness occurred after the end of surgery and these were commonly caused by neuromuscular blockade still being present when the patient regained consciousness [1] . Processed EEG monitoring should, therefore, be continued until full recovery from the effects of the neuromuscular blockade has been confirmed by monitoring with a nerve stimulator.
Processed EEG monitors provide much more information to the anaesthetist than just a derived index 
TIVA in particular circumstances
Rapid sequence induction
Rapid sequence induction may be undertaken before the maintenance of anaesthesia with an i.v. infusion of propofol. If TCI propofol is used for the induction of anaesthesia, this can be achieved by setting an initial high target concentration so the induction 'bolus' dose of propofol is delivered as a rapid infusion (e.g. 1200 ml.h À1 ), and then reducing the target concentration once the desired dose has been administered. (Many pumps will display the bolus dose to be given for a set target concentration before the start button is pressed). Some newer TCI pumps can run bolus infusion rates of 1800-2200 ml.h À1 . When using a TCI propofol pump for rapid sequence induction, the induction dose of propofol is typically delivered more slowly than a manual bolus. The time to loss of consciousness may be reduced by coadministration of other drugs with a rapid onset such as remifentanil or alfentanil. If the induction propofol bolus is given manually rather than by the TCI pump, then the estimated plasma propofol concentration displayed by the pump will not be accurate in the early phase of the anaesthetic. An alternative approach is to use a bolus of a different drug such as thiopentone or etomidate for the rapid sequence induction and then use TCI propofol for maintenance of anaesthesia. If ketamine is given, then paradoxical increases in pEEG index value may occur [35] .
Switching from inhalational anaesthesia to TIVA
When switching from inhalational anaesthesia to TIVA, it is important to ensure that an adequate brain concentration of 
Obstetrics
This guideline makes no recommendation on the routine use of TIVA in obstetric anaesthesia. This is an area which requires further research. In situations where TIVA is required (e.g. the transfer of an anaesthetised patient to the ICU), the principles in this guideline apply.
General anaesthesia in the intensive care unit (ICU)
These guidelines are not intended to apply to sedation of patients in the ICU.
When general anaesthesia is required in the ICU, for the performance of a surgical or diagnostic procedure, then TIVA is almost invariably used. Similar considerations should apply as for the use of TIVA in the operating theatre.
Total intravenous anaesthesia may be administered using either a manual propofol infusion or a TCI pump. However, the propofol pharmacokinetic models in TCI pumps were developed from studies involving healthy patients or subjects. These models are unlikely to accurately predict the plasma propofol concentration in critically ill patients with organ dysfunction. Furthermore, the calculation of predicted concentration will not take account of any propofol administered for ICU sedation before the TCI pump is used. Therefore, titration to clinical effect rather than relying on the estimated drug concentration displayed on the pump is likely to be appropriate. Processed EEG monitoring may be useful in ICU patients receiving TIVA although data on its use are limited.
TIVA in paediatric practice
Anaesthetists providing infusion anaesthesia to children require specific knowledge, recognising the pharmacological and practical differences in this age range.
The two widely used and validated paediatric TCI programmes which target plasma propofol concentration are the Kataria [8] and Paedfusor [9] models. The Kataria Pain on induction is common and can be reduced by prior administration of i.v. lidocaine, opioids or nitrous oxide. A target of 5-6 lg.ml À1 will usually be sufficient for rapid induction of anaesthesia. When switching to TIVA following a gaseous induction it is important to avoid an inadequate effect-site concentration. This may be achieved by setting an initial propofol target of 4 lg.ml À1 and decreasing the target after the pump indicates that a 2-3 mg.kg À1 bolus has been delivered (which typically takes 60-120 s). When using an analgesic adjunct such as remifentanil or a regional block, the propofol target concentration during maintenance can be reduced by up to 50% [34] . This is important in children aged < 12 years, as a target concentration of 5-6 lg.ml À1 soon leads to accumulation of propofol, resulting in delayed recovery after anaesthesia. A target propofol concentration of 2.5-4 lg.ml À1 is generally adequate during the maintenance of anaesthesia for cases lasting > 30 min when an opioid is also given. In some circumstances the required target concentrations may fall outside of this range. Titration to effect and clinical judgement are always necessary.
Remifentanil is commonly used with propofol infusions.
Children aged < 8 years tend to be less sensitive to its effects, tolerating larger doses when breathing spontaneously and requiring higher doses to produce a given antinociceptive effect [36, 37] . Target-controlled infusion of remifentanil can be administered using adult targets and the Minto model for patients aged ≥ 12 years and weighing ≥ 30 kg. For smaller children, it is necessary to use a manual infusion, for example, 0.2-0.5 lg.kg À1 .min À1 as a TCI model is not yet available.
Propofol-related infusion syndrome (PRIS) is a very rare, but potentially fatal, condition associated with propofol infusion. Interference with mitochondrial energy production leads to rhabdomyolysis, acidaemia and multi-organ failure. Risk factors include: prolonged infusion; high propofol delivery rate (> 6 mg.kg À1 .h À1 ); critical illness; low sugar intake; and co-administration of catecholamines and steroids [38] . It is even rarer in the Processed EEG monitoring may be used to guide TIVA administration in children. However, the effects of anaesthetic agents on the EEG in children under the age of 1 year differ from those in older children and adults [39] . Processed EEG monitoring is recommended when a neuromuscular blocking drug is administered in children aged > 1 year.
Training and competency in TIVA
All anaesthetists need to be able to deliver TIVA competently as they may encounter situations where administration of an inhaled anaesthetic is not possible.
However, surveys have found that not all anaesthetists in the UK and Ireland are gaining adequate knowledge and experience in the use of TIVA [1, [40] [41] [42] . 
Schools of
Pharmacokinetic principles and models for total intravenous anaesthesia (TIVA)
A pharmacokinetic model is a mathematical description of the distribution, metabolism and elimination of a drug in the body. The pharmacokinetic behaviour of most anaesthetic drugs used for TIVA can be predicted with a three-compartment model (Fig. S1 ). The drug is administered into the central compartment (V 1 ), which represents the initial volume of distribution. The second (V 2 ) and third (V 3 ) compartments are mathematical constructs explaining rapid and slow redistribution of drug from V 1 into highly perfused and less well perfused tissues, respectively. Rate constants describe the proportion of drug moving between compartments, for example, k 12 indicates the movement from V 1 to V 2 , and k 21 the movement from V 2 to V 1 . A metabolic rate constant (k 10 ) describes the proportion of drug in V 1 that is metabolised or eliminated in any unit of time. Finally, a rate constant k e0 describes the transfer from the central compartment to the effect-site (brain). The k e0 describes the speed of equilibration between plasma and brain; a higher k e0 equates to more rapid equilibration.
These volumes and rate constants are determined from studies in which the drug is administered to volunteers or patients by bolus, infusion or both, following which timed blood samples are taken to assay drug concentrations. In some studies, propofol concentration was measured in whole blood whereas in others it was measured in plasma.
There is a slight difference between whole blood and plasma concentrations but for simplicity we have used the term plasma concentration throughout this document.
Mathematical modelling software is used to estimate these pharmacokinetic variables in individual subjects, and then to estimate the influence of potential covariates such as body weight and age on these variables. Finally, a population model is developed, incorporating significant covariates. Importantly, different pharmacokinetic models use quite different covariates and pharmacokinetic variables.
Anaesthesia may be induced and maintained either using manual dosing where the anaesthetist determines the bolus dose(s) and infusion rates to be used or using a target controlled infusion (TCI) pump. A TCI pump contains a microprocessor programmed with pharmacokinetic models for relevant drugs.
How does a TCI pump achieve and maintain the programmed plasma concentration?
The user selects the drug and pharmacokinetic model to be used by that TCI pump, and inputs the patient characteristics (covariates) and the desired ('target') initial blood concentration. Once started, the system delivers a bolus as a fast infusion (600-1200 ml.h À1 ) to achieve the target concentration in V 1 (Fig. S2a ). During use, the pump software calculates the estimated amount of drug in each compartment every 10 s. It calculates the net amount of drug required over the following 10 s which depends on the target concentration, estimated drug metabolised and the net movement of drug between V 1 and V 2 , and between V 1 and V 3 . For a stable plasma concentration, the amount of drug metabolised per minute is constant, while the net movement of drug between compartments gradually decreases as gradients equalise. If the target concentration is unchanged, the pump will thus slowly decrease the infusion rate. If the target concentration is increased by the anaesthetist, a new bolus will be administered and the infusion rate increased. If the target concentration is decreased, drug infusion will pause until the plasma concentration is estimated to have fallen to the new target, taking into account metabolism and flux of drug between compartments, at which time the infusion will restart at a lower rate.
What is effect-site targeting?
Effect-site targeting is a TCI mode in which the user inputs a target effect-site (brain) concentration (Fig. S2b) . When the effect-site target concentration is increased a bolus of drug is administered, raising the plasma concentration higher than the effect-site target, to hasten the increase in effectsite concentration. However, when plasma concentration targeting is used, a similar effect can be achieved on induction by setting a higher initial plasma target which is reduced after the patient has lost consciousness.
With effect-site targeting, the size of the bolus and the 'overshoot' in plasma concentration depends considerably on the V 1 , V 2 and k e0 in the pharmacokinetic model. When the effect-site target concentration is decreased, the system stops infusing drug until the estimated effect-site concentration has decreased to the new target.
Key differences between common propofol models
The two most commonly used adult propofol models are Marsh [1] and Schnider [2, 3] models. Both were derived from studies involving healthy adults and did not include obese or older patients [4] . The Marsh model is the simplest. 
Manual infusion for propofol
For general anaesthesia, the 'Roberts' (or Bristol) regimen for propofol has been commonly used [5] . It involves a loading bolus of 1 mg.kg À1 followed by a step-down infusion scheme (10 mg.kg À 1.h À1 for the first 10 min, 8 mg.kg À1 .h À1 for the next 10 min, and then 6 mg.kg À1 .h À1 thereafter). For an average healthy young adult of normal proportions, this scheme will achieve a plasma concentration of approximately 3 lg.ml À1 . However, that concentration is not appropriate for all patients and may be inadequate for some but excessive for others. The concentration required is affected by other drugs given and in the study by Roberts et al., temazepam premedication, intravenous fentanyl and inhaled nitrous oxide were all given in addition to propofol [5] .
If the anaesthetist using a manual infusion wishes to achieve a higher plasma propofol concentration, an additional bolus is administered and the infusion rate increased. To reduce the plasma propofol concentration, the infusion is paused for a period and then recommenced at a lower rate. However, determining the size of an additional bolus or the duration of a pause in an infusion, and the subsequent infusion rates is difficult.
TCI and manual infusion for remifentanil
The Minto model is a validated model for remifentanil, and can be used for plasma or effect-site targeted TCI in patients aged ≥ 12 yr, and weighing ≥ 30 kg [6, 7] . Covariates incorporated in this model include age, weight, height and sex. From the latter three covariates, lean body mass is calculated, but the calculation is only valid in patients who have a BMI < 35 kg.m À2 in females and < 42 kg.m À2 in males.
Typical maintenance doses of remifentanil are in the order of 0.08-0.25 lg.kg À1 .min À1 which are equivalent to plasma concentrations of approx. 2-6 ng.ml À1 (Table S1 ).
In older patients, the plasma concentration resulting from a given infusion rate is higher, whilst in children it is lower. In young or middle-aged healthy adults of normal proportions, a plasma concentration appropriate for tracheal intubation (approximately 6 ng.ml À1 ) can be achieved reasonably quickly by giving a loading dose in the form of an initial rapid infusion of 0.5 lg.kg À1 .min À1 with a step down to 0.25 lg.kg À1 .min À1 after 3 min. Giving a bolus loading dose manually from a syringe is not recommended because that technique may result in an excessively high peak remifentanil concentration leading to severe bradycardia and chest wall rigidity.
Paediatric considerations
Compartment volumes in children are about twice the size of those in adults in comparison with their body weight. This difference gradually reduces from around 12 years of age, reaching adult values at 16 year. Thus, to achieve a given plasma concentration, children require larger propofol bolus doses and initial infusion rates relative to body weight than adults.
During prolonged infusion of propofol in children aged < 12 year, drug accumulation in the peripheral compartment occurs to a greater extent than in adults. Therefore, when the infusion is stopped, it typically takes longer in a child for the propofol concentration to decline to a level at which consciousness is regained than in an adult [8, 9] . Propofol requirements can be reduced, and speed of emergence improved, by remifentanil (or other opioid) coadministration, and the use of other drugs such as nitrous oxide, ketamine and a 2 agonists. Most children regain consciousness at an estimated propofol plasma concentration of approximately 2 lg.ml À1 , but this can vary considerably from 1 to 3 lg.ml À1 depending on interindividual differences and the use of adjunctive drugs [10] .
The two widely available and validated paediatric models which target plasma propofol concentration are Kataria [11] for ages 3-16 years and Paedfusor [12] for ages 1-16 years. Kataria can be used in children weighing 15-61 kg and Paedfusor 5-61 kg. Effect-site targeting has not been implemented in paediatric TCI systems. For an average length procedure in a young child, both models administer approximately 50% more propofol than in an adult using the Marsh model, which is why adult models should not be used in this age group. If a propofol manual infusion is used in children the initial bolus and subsequent infusion rates need to be higher than in adults [13] .
Appendix References
Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article. Table S1 . Remifentanil plasma concentrations (ng.ml À1 ) achieved at steady state, estimated by the Minto model in a 70-kg, 170-cm, 40-yr-old male patient for various fixed infusion rates. In older patients, the plasma concentration resulting from a given infusion rate is higher, whereas in children it is lower. 
